Edward Li’s biosimilars research featured by Pharmacy Times
Research on biosimiliars by Edward Li, Pharm.D., M.P.H., BCOP, associate professor in the UNE Department of Pharmacy Practice, was recently featured in the article in Pharmacy Times.
The 2010 Affordable Care Act paved the way for FDA approval of biosimilars. With many blockbuster biologics’ patents expiring, pharmacists can expect change, and potentially, lower costs.
It is important that pharmacists educate themselves so they can properly inform patients about the safe and effective use of biosimilars, according to copresenter James Stevenson, PharmD, FASHP, of the ¸ßÇå²»¿¨¸£Àû of Michigan.
Biologics’ issues are unique compared with those of simple molecules. With biologics’ living cell culture sources, comparatively high molecular weights, complex folding, variable stability, and immunogenic properties (which create antibodies or neutralizing products), stakeholders have been concerned that demonstrating true interchangeability would be impossible.